Related references
Note: Only part of the references are listed.PROGNOSTIC SIGNIFICANCE OF NEUROENDOCRINE DIFFERENTIATION IN PATIENTS WITH GLEASON SCORE 8-10 PROSTATE CANCER TREATED WITH PRIMARY RADIOTHERAPY
Daniel J. Krauss et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
DOSE ESCALATION IMPROVES CANCER-RELATED EVENTS AT 10 YEARS FOR INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER PATIENTS TREATED WITH HYPOFRACTIONATED HIGH-DOSE-RATE BOOST AND EXTERNAL BEAM RADIOTHERAPY
Alvaro A. Martinez et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Christopher U. Jones et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Himisha Beltran et al.
CANCER DISCOVERY (2011)
Long-Term Assessment of Prostate Cancer Progression Free Survival: Evaluation of Pathological Parameters, Nuclear Shape and Molecular Biomarkers of Pathogenesis
Robert W. Veltri et al.
PROSTATE (2008)
Unusual and underappreciated: Small cell carcinoma of the prostate
Jeffrey S. Palmgren et al.
SEMINARS IN ONCOLOGY (2007)
Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy
Matthias May et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2007)
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of Phase III RTOG 85-31
MV Pilepich et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: Analysis of chronic toxicity
D Brabbins et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities
N Vashchenko et al.
EUROPEAN UROLOGY (2005)
Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: Use of dose-volume constraints to achieve rectal isotoxicity
C Vargas et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer - A randomized controlled trial
AV D'Amico et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
The role of androgens and the androgen receptor in prostate cancer
JD Debes et al.
CANCER LETTERS (2002)
Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma
T Fixemer et al.
PROSTATE (2002)
Neuroendocrine expression in node positive prostate cancer: Correlation with systemic progression and patient survival
DG Bostwick et al.
JOURNAL OF UROLOGY (2002)
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
M Bolla et al.
LANCET (2002)
Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer
AA Martinez et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways
T Ueda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume
G Ahlgren et al.
UROLOGY (2000)
Share Paper
